A Retrospective Cohort Study About Surgical Efficacy for Lower Cervical Fractures in Ankylosing Spondylitis
Launched by ZHOU FANG · Mar 7, 2025
Trial Information
Current as of April 26, 2025
Completed
Keywords
ClinConnect Summary
This was a retrospective cohort study. Patients operated for fracture-dislocation of the lower cervical vertebrae in ankylosing spondylitis in our hospital from 01/2014 to 01/2024 were retrospectively included as study subjects. Prior to the start of the study, an application will be made for approval through the hospital ethical committee, and the Declaration of Helsinki will be observed during the course of the study. The patients were divided into an anterior group (anterior long-segment cervical fixation), a posterior group (posterior long-segment cervical fixation), and a combined grou...
Gender
ALL
Eligibility criteria
- Inclusion criteria:
- • Meet the diagnostic criteria for ankylosing spondylitis, imaging showed that cervical ankylosing and fracture dislocation of the lower cervical vertebrae (cervical 3\~7); Age 18\~80 years old; undergo anterior, posterior or combined access internal fixation surgery and the fixation segment is ≥4 segments.
- Exclusion criteria:
- • Systemic or local infection; Previous history of cervical vertebrae surgery; Postoperative loss of follow-up.
About Zhou Fang
Zhou Fang is a leading clinical trial sponsor dedicated to advancing medical research and innovative therapies. With a strong focus on patient-centered approaches, Zhou Fang collaborates with healthcare professionals and research institutions to design and conduct rigorous clinical trials across various therapeutic areas. The organization prioritizes safety, efficacy, and ethical standards, ensuring that every study contributes valuable insights to the scientific community. Committed to fostering advancements in healthcare, Zhou Fang plays a pivotal role in transforming research findings into effective treatment options for patients worldwide.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Beijing, Beijing, China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported